Gut Dysbiosis as a Potential Guide for Immunotherapy (Dis)Continuation After 2 Years in NSCLC: A Brief Report

Background: Although most phase III pivotal trials have set the duration of immune checkpoint blockers (ICB) for advanced NSCLC at 2 years, the criteria for safely discontinuing ICB remain undefined. Growing evidence links ICB efficacy to gut microbiota, positioning gut microbial taxonomic profiling...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Adele Bonato, MD, Claudia Parisi, MD, Priscilla Cascetta, MD, Anna Reni, MD, May-Lucie Meyer, MD, Mariona Riudavets, MD, PhD, David Planchard, MD, PhD, Benjamin Besse, MD, PhD, Jordi Remon, MD, Francesco Facchinetti, MD, PhD, Lorenzo Belluomini, MD, PhD, Lisa Derosa, MD, PhD, Fabrice Barlesi, MD, PhD
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Elsevier 2026-01-01
Σειρά:	JTO Clinical and Research Reports
Θέματα:	NSCLC Immunotherapy Duration (Dis)continuation Gut microbiome
Διαθέσιμο Online:	http://www.sciencedirect.com/science/article/pii/S2666364325001468
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!